LINC02887: A Long Intergenic Non-Protein-Coding RNA and Its Potential as a Drug Target

Target Name: LINC02887

NCBI ID: G105377826

LINC02887

Other Name(s): Long intergenic non-protein coding RNA 2887, transcript variant X17 | LINC02887 variant X17 | long intergenic non-protein coding RNA 2887

LINC02887: A Long Intergenic Non-Protein-Coding RNA and Its Potential as a Drug Target

LINC02887 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature, which is its ability to interact with proteins and play a critical role in various biological processes. LINC02887 is a good candidate for being a drug target or biomarker due to its unique function and the potential it holds for future scientific research.

Structure and Expression

LINC02887 is a transcribed RNA molecule that contains 2887 exons. It is characterized by the presence of a stem-loop structure, which is a common feature in non-coding RNAs. The stem-loop region of LINC02887 is responsible for its unique interaction with proteins.

Expression of LINC02887

LINC02887 is expressed in various tissues and cells in the body. It is highly expressed in the brain, heart, and liver, which are known to be critical organs for the proper functioning of the body. The expression pattern of LINC02887 may vary depending on the specific cell type and the organism in which it is expressed.

Drug Target Potential

LINC02887 has been shown to interact with various proteins, including the protein known as heat shock protein (HSP70). HSP70 is a protein that is expressed in high levels in various tissues and cells, including the brain. It plays a critical role in stress responses and is known to be involved in a variety of cellular processes, including DNA replication, protein folding, and cell signaling.

The interaction between LINC02887 and HSP70 suggests that LINC02887 may have potential as a drug target for the treatment of various diseases that are associated with HSP70 dysfunction. For example, HSP70-related diseases, such as neurodegenerative diseases, may benefit from LINC02887-based therapies since HSP70 is known to be involved in the development and progression of these diseases.

Biomarker Potential

The expression pattern of LINC02887 may also be used as a biomarker for various diseases. For example, LINC02887 may be used as a biomarker for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. The expression patterns of these diseases are often altered in ways that are similar to LINC02887, which suggests that LINC02887 may be a useful biomarker for the diagnosis and treatment of these diseases.

Conclusion

LINC02887 is a long non-coding RNA that has unique features, including its ability to interact with proteins. Its expression pattern varies depending on the tissue and cell type, but it is highly expressed in the brain, heart, and liver. The interaction between LINC02887 and the protein known as HSP70 suggests that LINC02887 may have potential as a drug target for the treatment of various diseases associated with HSP70 dysfunction. Additionally, the expression pattern of LINC02887 may also be used as a biomarker for neurodegenerative diseases. Further research is needed to determine the full potential of LINC02887 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2887

The "LINC02887 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02887 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets